Suvorexant in Insomnia Co-morbid With Fibromyalgia

• Status: Terminated
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henry Ford Health System
• Treatments: Suvorexant

Criteria

Inclusion Criteria:

• meet Diagnostic and Statistical Manual 5th ed criteria for insomnia

• meet American College of Rheumatology criteria for fibromyalgia

• otherwise good psychiatric and stable physical health

Exclusion Criteria:

• other primary sleep disorders

• pain symptoms unrelated to fibromyalgia

• current pregnancy or breast-feeding